<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572362</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-Nr. 2014-0255</org_study_id>
    <nct_id>NCT02572362</nct_id>
  </id_info>
  <brief_title>Secondary Cancer Risk After Radiation Therapy for Rectal Cancer</brief_title>
  <official_title>Estimation of Second Cancer Risk in Patients Planned With Different Radiotherapy Regimes for Rectal Cancer - A Planning Study and Model-based Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Graubuenden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinik Hirslanden, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kantonsspital Graubuenden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective study comparing dose distribution of 3D conformal radiotherapy (3DCRT) and
      volumetric-modulated arc therapy (VMAT) to estimate secondary cancer risk for patients having
      had radiation therapy for rectal cancer. Twenty-five patients are included in this study.
      Planning CT scans are used for comparison of dose distribution and calculation of second
      cancer risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A model-based Analysis calculating the organ-specific excess lifetime attributable risk using
      the planning CT data sets of 25 patients to estimate second cancer risk for patients after
      radiotherapy for rectal cancer comparing conventional 3DCRT with VAMT techniques.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calculation of the organ-specific excess lifetime attributable risk (LAR) (%)</measure>
    <time_frame>60 years (model-based calculation)</time_frame>
    <description>LAR is calculated for variable Ages at exposure</description>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Neoplasms, Second Primary</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention in this retrospective study</intervention_name>
    <description>No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having had radiation therapy for rectal cancer. Estimation of second cancer risk
        using data from planning CTs comparing dose Distribution using different Radiation therapy
        techniques (3DCRT vs VMAT).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female &gt; 18 years of age

          -  pre or postoperative radiation therapy for rectal cancer

          -  Planning CT

        Exclusion Criteria:

          -  Planning CT not available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel R Zwahlen, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Graubuenden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik Hirslanden, Institute for Radiotherapy</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>December 11, 2016</last_update_submitted>
  <last_update_submitted_qc>December 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Graubuenden</investigator_affiliation>
    <investigator_full_name>Daniel Rudolf Zwahlen</investigator_full_name>
    <investigator_title>MD, MBA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

